Jingli Xu Selected Research

triazacyclononane

1/2022	Novel Al18F-NOTA-Conjugated Lactam-Cyclized α-Melanocyte-Stimulating Hormone Peptides with Enhanced Melanoma Uptake.
1/2022	Novel 64Cu-Labeled NOTA-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptides with Enhanced Tumor to Kidney Uptake Ratios.
12/2020	Facile preparation of a novel Ga-67-labeled NODAGA-conjugated lactam-cyclized alpha-MSH peptide at room temperature for melanoma targeting.
1/2020	Novel [99mTc]-Tricarbonyl-NOTA-Conjugated Lactam-Cyclized Alpha-MSH Peptide with Enhanced Melanoma Uptake and Reduced Renal Uptake.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jingli Xu Research Topics

Disease

18	Neoplasms (Cancer) 02/2022 - 08/2009
11	Melanoma (Melanoma, Malignant) 02/2022 - 04/2015
4	Brain Neoplasms (Brain Tumor) 07/2012 - 08/2009
3	Stomach Neoplasms (Stomach Cancer) 02/2022 - 01/2022
3	Prostatic Neoplasms (Prostate Cancer) 07/2018 - 02/2015
2	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2020
2	Glioblastoma (Glioblastoma Multiforme) 07/2018 - 02/2015
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2020
1	Arteriovenous Fistula 01/2020
1	Cicatrix (Scar) 04/2018
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2017

Drug/Important Bio-Agent (IBA)

12	Peptides (Polypeptides)IBA 02/2022 - 02/2015
8	AcidsIBA 02/2022 - 04/2010
8	alpha-MSHIBA 02/2022 - 04/2015
8	LactamsIBA 01/2022 - 10/2016
7	Type 1 Melanocortin ReceptorIBA 02/2022 - 11/2018
4	triazacyclononaneIBA 01/2022 - 01/2020
4	(18F)fluoroethyltyrosineIBA 07/2012 - 08/2009
4	Biological ProductsIBA 03/2012 - 08/2009
3	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 01/2022 - 01/2020
3	Melanocyte-Stimulating Hormones (MSH)IBA 01/2022 - 11/2019
3	pyrimidineIBA 03/2012 - 11/2010
2	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 02/2022 - 02/2015
2	1- (1,3- carboxypropyl)- 4,7- carboxymethyl- 1,4,7- triazacyclononaneIBA 12/2020 - 01/2020
2	Chelating AgentsIBA 12/2020 - 01/2020
2	BombesinIBA 07/2018 - 02/2015
2	IntegrinsIBA 07/2018 - 02/2015
2	RadiopharmaceuticalsIBA 02/2015 - 11/2010
2	compound 18IBA 08/2011 - 04/2010
1	AlbuminsIBA 02/2022
1	Tumor Biomarkers (Tumor Markers)IBA 02/2022
1	1-Butanol (n Butanol)IBA 01/2022
1	Ethylene Glycol (Monoethylene Glycol)IBA 01/2022
1	Indicators and Reagents (Reagents)IBA 01/2022
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2022
1	SynteninsIBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	huaierIBA 01/2022
1	phenylalanylarginineIBA 12/2020
1	MetalsIBA 01/2020
1	terphenyllinIBA 01/2020
1	Radioisotopes (Radionuclides)IBA 11/2018
1	OxidesIBA 04/2018
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 10/2017
1	AntigensIBA 10/2017
1	arginyl-glycyl-aspartic acidIBA 04/2015
1	Bombesin Receptors (Bombesin Receptor)IBA 02/2015
1	LigandsIBA 02/2015
1	QuinazolinesIBA 09/2013
1	Sorafenib (BAY 43-9006)FDA Link 09/2013
1	Mechlorethamine (Nitrogen Mustard)FDA Link 09/2013
1	4-aminoquinazolineIBA 07/2012
1	benzimidazoleIBA 04/2010
1	Butyric Acid (Butanoic Acid)IBA 04/2010
1	Tyrosine (L-Tyrosine)FDA Link 08/2009

Therapy/Procedure

6	Therapeutics 01/2022 - 02/2015
2	Precision Medicine 01/2022 - 07/2018
2	Intravenous Injections 07/2018 - 02/2015
1	Perioperative Period 02/2022
1	Neoadjuvant Therapy 02/2022
1	Immunotherapy 01/2022
1	Renal Dialysis (Hemodialysis) 01/2020
1	Local Anesthesia 01/2020